Anthracycline Therapy Selection via HER2 Subtyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, such as anthracycline-based treatments, have severe side effects like cardiotoxicity and secondary leukemia, necessitating a method to determine which cancer types respond best to anthracycline therapy and which should be treated with alternative therapies.
Innovation Solution
A method involving the classification of breast cancer subtypes using fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) to identify Her2+ and Her-2-E subtypes, followed by administering anthracycline-based treatments only to those classified as both Her2+ and Her-2-E subtypes, while using alternative treatments for others.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anthracycline-based therapy is administered to treat breast cancer, then treatment efficacy is improved, but severe side effects such as cardiotoxicity and secondary leukemia occur
Solution Approach 1:
The patent segments breast cancer patients into distinct molecular subtypes (HER2-enriched, luminal A, luminal B, basal-like) based on gene expression profiles. This segmentation allows identification of the specific subgroup (HER2-enriched) that benefits from anthracycline therapy, while sparing other subtypes from unnecessary exposure to toxic side effects.
Solution Approach 2:
The patent applies local quality by tailoring treatment to specific patient subgroups rather than applying a uniform treatment approach. Anthracycline therapy is selectively administered only to HER2-enriched breast cancer patients, who have specific molecular characteristics, while alternative therapies are used for other subtypes, thereby optimizing efficacy while minimizing harm.
2Reliability
If anthracycline therapy is administered to all breast cancer patients, then potential treatment benefit is maximized, but unnecessary exposure to severe side effects increases
Solution Approach 1:
The patent employs preliminary action by performing molecular subtyping analysis before treatment decisions are made. Gene expression profiling is conducted in advance to identify HER2-enriched subtype, allowing clinicians to pre-determine which patients will benefit from anthracycline therapy and which should receive alternative treatments, thus avoiding unnecessary side effects from the outset.
Solution Approach 2:
The patent utilizes feedback mechanisms through molecular subtyping that provides information about patient-specific tumor characteristics. This feedback loop allows treatment recommendations to be adjusted based on the identified subtype, ensuring anthracycline is only prescribed when molecular evidence suggests it will be beneficial, thereby preventing unnecessary harm.
3Adaptability or versatility
If molecular subtyping analysis is performed to guide treatment selection, then personalized treatment optimization is achieved, but diagnostic complexity and cost increase
Solution Approach 1:
The patent applies universality by using a single molecular subtyping assay (PAM50 gene expression profile) that simultaneously classifies tumors into multiple subtypes (HER2-enriched, luminal A, luminal B, basal-like) and provides prognostic information. This multi-functional diagnostic tool replaces the need for multiple separate tests, reducing overall diagnostic complexity while enabling personalized treatment decisions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for personalized breast cancer treatment by optimizing the use of anthracycline therapy, reducing severe side effects and improving treatment efficacy based on specific cancer subtypes.
Implementation Method 1
The assaying of the biological sample to determine whether the biological sample is classified as a Her2+ subtype is performed using fluorescence in situ hybridization (FISH)
Implementation Method 2
The assaying of the biological sample to determine whether the biological sample is classified as a Her2+ subtype is performed using fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC)
Data Source
AI summary
The application describes methods for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including an anthracycline. The application also describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including anthracycline and administering the therapy in subjects when it is found that anthracycline is likely to be effective.